Methods
We analyzed data in 2445 cases after we had obtained approval from our local institutional review board. The database contained information from two patient cohorts studied retrospectively: the Chiba series, composed of 1716 consecutively enrolled patients treated between January 1998 and March 2008; and the Tokyo series, composed of 729 patients treated between April 2008 and December 2011. All aspects of patient selection, radiation dose planning, dose selection, performance of GKS, and collection of follow-up data were undertaken by the first author (T.S.). During the 14-year period from 1998 to 2011, all these patients were treated according to the same protocol, as reported previously. [8] [9] [10] [11] At the initial treatment, all lesions were irradiated by SRS without upfront WBRT. In some cases in which tumor volumes exceeded 10 cm 3 , staged SRT was chosen 4 ; and in all cases in which the total tumor volume exceeded 20 cm 3 and/or the number of tumors was greater than 25, the radiosurgical procedure was divided into 2 or 3 sessions to ensure a total skull integral dose of less than 10 J, thereby preventing acute brain swelling. 11, 15 New distant lesions, detected by Gd-enhanced MR imaging, which was performed every 2-3 months, were treated mainly with GKS, although if cerebral or CSF tumor dissemination was detected, these lesions were treated with WBRT. The treatment strategy was explained in detail to each patient, and written informed consent was obtained from all patients before GKS.
After the patient had received relatively deep sedation and a local anesthetic agent had been applied to the patient's head, a stereotactic coordinate frame (Leksell model G stereotactic coordinate frame, Elekta AB) was affixed to the head. For target coordinate determination and dose-planning, stereotactic Gd-enhanced T1-weighted axial MR images (slice thickness 2 mm, multiple slices) covering the entire brain were obtained. For dose planning, we used the Leksell GammaPlan (Elekta). We used a Leksell Gamma Knife (Elekta) for all procedures: before October 2003 October (1988 October -2003 , we performed GKS using model B; from October 2003 to November 2011, we used model C; and from December 2001 onward, we used the model Perfexion. The standard prescribed dose directed to the tumor periphery, 18-24 Gy, was changed depending on the pathological characteristics of the tumor, the patient's physical status, the tumor location and volume, the status of the patient's extracranial disease, and so forth.
All data were analyzed according to the intention-totreat principle. The intervals from the date of GKS until the date of death (overall survival) and impaired activities of daily living (qualitative survival) were calculated using the Kaplan-Meier method. 5 The estimated absolute risk for two adjacent classes of each grading system, as well as hazard ratios and 95% confidence intervals, were calculated using the Cox proportional hazards model. Prognostic values for overall survival were also calculated using the Cox proportional hazard model, which considered 14 factors: patient age and sex, initial KPS score, primary site of the lesion, number of tumors, total tumor volume, MR imaging findings of CSF dissemination, craniotomy, chemotherapy, lag between diagnosis of primary cancer and brain metastasis, prior WBRT, maximum tumor diameter, neurological symptoms, and status of the extracranial disease. Impaired activities of daily living were defined as an impaired neurological status that is reflected by a KPS score 6 < 70%, as reported by Aoyama et al. 1 Thus, cases without improvement to KPS scores of ≥ 70%³, even after GKS, were excluded when evaluating the qualitative survival. The differences between two adjacent classes were compared using the log-rank test. A p value less than 0.01 was defined as statistically significant. All statistical analyses were performed using the JMP software program, version 9.0.3 (SAS Institute Inc.).
Results
At the end of December 2011, 353 patients (14.4%) were still alive, and the remaining 2092 patients (85.6%) were confirmed to have died. Table 1 summarizes the demographic characteristics of the patients. The median overall survival time was 7.8 months. The cumulative overall survival rates were 60.0% at 6 months, 35.4% at 12 months, 15.8% at 24 months, 9.4% at 36 months, 4.0% at 60 months, and 0.1% at 120 months after GKS. The cumulative qualitative survival rates were 90.5% at 6 months, 80.3% at 12 months, 64.3% at 24 months, 56.0% at 36 months, 43.2% at 60 months, and 23.3% at 120 months after the procedure. Among the 2092 deceased patients, the causes of death were determined to be brain diseases in 298 patients (14.2%) and systemic diseases in 1794 patents (85.8%). Salvage repeated GKS procedures for new distant and/or recurrent brain metastases after the initial GKS were required in 1031 patients (42.2%) and salvage WBRT in 95 patients (3.9%).
Figures 1-5 demonstrate overall survival and qualitative survival curves according to the 5 major grading systems ( Fig Tables 2 and 3 , and those for qualitative survival can be found in Table 4 . As shown in Table 2 , the RPA, SIR, and GPA grading systems had large discrepancies in patient numbers among groups. A total of 81.1% of patients were classified as RPA Class II and 76.1% as SIR Scores 4-7, whereas only 1.7% were GPA Scores 3.5-4.0 and 5.3% were GPA Score 3.0. The RPA, SIR, BSBM, and modified RPA grading systems showed statistically significant differences among subclasses (p < 0.0001 for all adjacent subclasses). Looking at the GPA system, however, one found that the difference between GPA Scores 3.5-4.0 and GPA Score 3.0 did not reach statistical significance (p = 0.3750). Table 3 shows poor prognostic factors for overall survival that were verified. The final multivariate analysis model revealed 4 highly significant poor prognostic factors (initial KPS score < 70%, primary lesion other than lung or breast, number of brain metastases; maximum diameter of the largest tumor > 25 mm; and active extracranial disease). On the contrary, only the SIR shows excellent statistical results for predicting preservation of neurological function, as shown in Table 4 . Although the other grading systems did not yield statistically significant differences, the BSBM and the modified RPA appear to be better for predicting qualitative survival.
Discussion
After Gaspar et al. 3 developed an index, based on the original Radiation Therapy Oncolology Group's RPA, for predicting life expectancies of patients with brain metastasis, 4 additional grading systems were proposed: the SIR, 14 the BSBM, 7 the GPA, 13 and the modified RPA.
14 The SIR and the modified RPA were derived from a database of patients treated radiosurgically. 14, 16 We applied these 5 grading systems to nearly 2500 patients treated with GKS alone. As shown in Table 2 , 4 of the 5 grading systems (specifically, the RPA, SIR, BSBM, and modified RPA) showed highly statistically significant differences when comparing pairs of adjacent classes (p < 0.001 for all). In this series, in which patients in Japan were only treated with GKS, 12,14 the difference between the GPA Score 3.5-4.0 and Score 3.0 groups did not reach statistical significance. These results were the same as those of Yamamoto's report on GKS-treated patients in Japan with quite similar backgrounds. In their report, the original RPA, as well as the SIR, BSBM, and modified RPA, were noted to be excellent grading systems for predicting overall survival. Unfortunately, all but the modified RPA have some faults. The BSBM does not incorporate brain disease status, that is, it does not include tumor number and tumor volume. On the other hand, although the SIR and GPA do include brain disease factors, their scoring seems rather complex for clinical use. There were large discrepancies in patient numbers among groups with the RPA, SIR, and GPA. Thus, we conclude that the modified RPA is well balanced and is the best grading system for the prediction of overall survival.
Preservation of function has been regarded as one of the ideal endpoints for evaluating treatment results for patients with brain metastases, even for those who undergo WBRT, surgical extirpation, SRT, or SRS. However, previous reports on grading systems for patients with brain metastases mention only overall survival and not preservation of function. We have followed up on patients with meticulous neurological examinations and enhanced MR imaging every 2-3 months, with special attention given to changes in performance status due to brain disease. We use "qualitative survival" to mean preservation of neurological function (equivalent to a KPS score of ≥70%), de- fined as no impairment due to any type of brain disease, that is, tumor recurrence, radiation injury, cerebral dissemination, CSF dissemination, and other brain diseases.
In this paper, we focused on which grading system is the best for predicting preservation of neurological function. From the standpoint of overall survival, 4 of the grading systems-all but the GPA-were excellent. Considering both overall and qualitative survival, however, the SIR appears to be the best grading system. These results allow us to conclude that patients with SIR scores of 8-10 are excellent candidates for GKS. Those with SIR scores of 4-7 are also good candidates, based on overall as well ). Indeed, brain disease factors, including tumor number, tumor location, maximum tumor number, total tumor number, and CSF dissemination, are considered crucial for choosing among treatment modalities including WBRT, craniotomy, SRT, SRS, and best supportive care. Thus, a new grading system for predicting both overall survival and qualitative survival and for selecting the best treatment for patients with brain metastasis is needed. The modified RPA, proposed by Yamamoto et al., 16 has the potential to resolve these problems. Its only disadvantage is the lack of a significant difference between Classes I and IIa, both of which contain relatively small numbers of patients, such that combining Classes I and IIa may be an option. However, a new grading system focused on qualitative survival, as well as on overall survival, is necessary. This would allow poor prognostic factors for qualitative survival to be analyzed in our large patient series treated with GKS.
Conclusions
Among the 5 major grading systems, four-the RPA, SIR, BSBM, and modified RPA-yielded highly statistically significant differences in our 2500 cases treated with GKS. For predicting preservation of function, which we consider to be the most important evaluation endpoint, the SIR was apparently the best, while the BSBM and the modified RPA also produced good statistical results. Unfortunately, the SIR scoring is overly complex for clinical use. Thus, a new simple grading system is necessary for the prediction of qualitative as well as overall survival and for selecting an optimal brain metastasis patient cohort for SRS.
